Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Bioorg Med Chem. 2013 Dec 15;21(24):7612-23. doi: 10.1016/j.bmc.2013.10.035. Epub 2013 Oct 31.
A novel class of phosphodiesterase 10A (PDE10A) inhibitors with reduced CYP1A2 inhibition were designed and synthesized starting from 2-{[(1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (1). Introduction of an isopropyl group at the 2-position and a methoxy group at the 5-position of the benzimidazole ring of lead compound 1 resulted in the identification of 2-{[(2-isopropyl-5-methoxy-1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (25b), which exhibited potent PDE10A inhibitory activity with reduced CYP1A2 inhibitory activity compared to compound 1.
设计并合成了一类新型的磷酸二酯酶 10A(PDE10A)抑制剂,该抑制剂对 CYP1A2 的抑制作用降低,以 2-{[(1-苯基-1H-苯并咪唑-6-基)氧基]甲基}喹啉(1)为起始原料。在先导化合物 1 的苯并咪唑环的 2-位引入异丙基和 5-位引入甲氧基,得到 2-{[(2-异丙基-5-甲氧基-1-苯基-1H-苯并咪唑-6-基)氧基]甲基}喹啉(25b),与化合物 1 相比,其对 PDE10A 的抑制活性更强,对 CYP1A2 的抑制活性更低。